Clinical Trials
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
S1900B
A PHASE II STUDY OF SELPERCATINIB (LOXO-292) IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
S1900B will close to accrual April 30, 2021, effective 12:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-10-2020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1900C
A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)
Status Notes
S1900C closed to accrual December 18, 2020.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-16-2020
Closed
12-18-2020
Open
Phase
Accrual
32%
SWOG Clinical Trial Number
S1827
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Status Notes
This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
01-10-2020
ClinicalTrials.gov Registry Number
04155034
Open
Phase
Accrual
34%
SWOG Clinical Trial Number
S1922
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Status Notes
Temporary Closure: Effective Wednesday, October 05, 2022, 12:00 p.m. Pacific Time
Research Committee(s)
Lymphoma
Activated
07-19-2019
Closed
12-01-2022
ClinicalTrials.gov Registry Number
03907488
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S1803
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Status Notes
This study is re-opened to patient accrual effective 11/15/2023.
Research Committee(s)
Myeloma
Activated
06-27-2019
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S1916
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients
Status Notes
This study is permanently closed effective September 16, 2020.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1800A
A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Status Notes
S1800A closed to accrual November 16, 2020.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
05-17-2019
Closed
11-16-2020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Status Notes
Study permanently closed to accrual as of 04/01/2024, noon PST.
Research Committee(s)
Genitourinary Cancer
Activated
04-19-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1714
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Status Notes
S1714 will permanently close to accrual on November 15, 2021 at 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1600
A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Status Notes
S1600 study will be permanently closed to accrual, effective 10/20/2023.
Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02-21-2019
Closed
10-20-2023
ClinicalTrials.gov Registry Number
NCT03757949
Closed
Phase
Accrual
1%
SWOG Clinical Trial Number
S1614
Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors
Status Notes
Active 2/21/19
Reactivation, effective 7/1/21
Reactivation, effective 7/1/21
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
02-21-2019
Closed
11-15-2022
ClinicalTrials.gov Registry Number
03887702
Closed
Phase
Accrual
73%
SWOG Clinical Trial Number
S1900A
A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA 1/2 MUTATION STAGE IV NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
S1900A is permanently closed to accrual, effective 2/1/21.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-29-2019
ClinicalTrials.gov Registry Number
NCT03845296
Open
Phase
SWOG Clinical Trial Number
LUNGMAP
A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Status Notes
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-28-2019
ClinicalTrials.gov Registry Number
NCT03851445
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1801
A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma.
Status Notes
Permanent Closure: Effective May 5, 2022, at 11:59 p.m. Pacific Time.
Research Committee(s)
Melanoma
Activated
12-06-2018
Closed
05-05-2022
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1815
A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
Status Notes
This study permanently closed to accrual effective 2/15/21.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-03-2018
Closed
02-15-2021
Open
Phase
Accrual
62%
SWOG Clinical Trial Number
S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Status Notes
Activated 9/17/18.
Research Committee(s)
Genitourinary Cancer
Other
Symptom Control and Quality of Life
Activated
09-17-2018
Open
Phase
Accrual
51%
SWOG Clinical Trial Number
S1706
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Status Notes
Activation, Effective 9/12/2018, 2:00 pm CT
Research Committee(s)
Breast Cancer
Activated
09-12-2018
ClinicalTrials.gov Registry Number
NCT03598257
Closed
Phase
Accrual
32%
SWOG Clinical Trial Number
S1701
A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Status Notes
Permanent Closure - Effective 09/29/2022
Research Committee(s)
Lung Cancer
Activated
08-09-2018
Closed
09-29-2022
ClinicalTrials.gov Registry Number
03694002
Closed
Phase
Accrual
96%
SWOG Clinical Trial Number
S1712
A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Status Notes
The study is closed to accrual effective 10/20/2022.
Research Committee(s)
Leukemia
Activated
07-20-2018
ClinicalTrials.gov Registry Number
NCT03654768